Dermatology Times, Evidence-Based Cleansing and Moisturizing Practices for Protecting and Repairing the Skin Barrier, November 2025 (Vol. 46. Supp. 09) ...
Yassky, MD, PhD, explains how biomarkers could match patients with inflammatory skin diseases to the right therapy. Emma ...
Dr Linda Stein Gold and Dr Michael Cameron assess the safety and tolerability of topical ruxolitinib cream, offering guidance on counseling patients about the black box warning. They also address the ...
IL-31 receptor targeting may differentiate nemolizumab by impacting pruritus-driven neuroimmune signaling while also modulating inflammation and epidermal barrier disruption. Correlative analyses ...
Two global randomized phase 3 studies evaluated ritlecitinib 100 mg (n=1567; exploratory 50 mg) and 50 mg (n=607; age ≥12), ...
Day 2 of EADV 2026 highlighted new findings involving GLP-1–associated nail changes, long-term atopic dermatitis control, emerging therapies, alopecia, and hidradenitis suppurativa. The second day of ...
Icotrokinra (Icotyde) produced skin clearance through 2 years in patients with plaque psoriasis affecting the scalp, genitals, hands, and feet, with 70% achieving clear or almost ...
Day 2 of EADV 2026 highlighted new findings involving GLP-1–associated nail changes, long-term atopic dermatitis control, emerging therapies, alopecia, and hidradenitis suppurativa. Phase 2b SPOTLIGHT ...
The National Eczema Association (NEA) has released the State of AD 2026 National Indicator Report, a Milliman analysis ...
ASC40-304 enrolled 240 completers from ASC40-303, administering denifanstat 50 mg QD for up to 40 additional weeks, with safety primary and efficacy assessed versus ASC40-303 baseline. IGA treatment ...
Intralesional BO-112 demonstrated promising clinical and pathological responses in patients with resectable basal cell ...
Trispecific blockade of IL-4/IL-13 and upstream TSLP is intended to broaden type 2 inflammatory pathway coverage and potentially enhance durability versus single-axis inhibition. Week-16 EASI 75 rates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results